Pulmonary arterial hypertension (PAH, WHO Group I) is a silently progressive disease1

Before 
Progression
Takes More Away

Add Uptravi Earlier in FC II and FC III

Uptravi: Proven to Delay PAH Progression
  • Enroll a Patient

    Get patients started on UPTRAVI

    Enroll Now
  • Support for patients during treatment

    Help patients start on therapy and set expectations for the dose adjustment phase

    Get Help Now
  • Triple-Combination SUBGROUP

    View triple-combination subgroup analyses

    See the Data
  • Time-From-Diagnosis SUBGROUPS

    View time-from-diagnosis subgroup analyses

    See the Data